{"database": "lobbying", "table": "lobbying_activities", "rows": [[2424072, "2b863c27-57f7-45dd-ad73-f683fc580bc9", "Q1", "JAMES EDWARDS", 401027897, "CONSERVATIVES FOR PROPERTY RIGHTS", 2020, "first_quarter", "CPT", "S. 2082/H.R. 3666 (STRONGER Patents Act)\nTrade-related intellectual property policy/practices/encroachment by foreign countries/companies against U.S. competitiveness interests - China, Committee on Foreign Investment in the United States review of Chinese acquisitions and joint ventures, United States-Mexico-Canada Agreement IP chapter, International Trade Commission exclusion of U.S. patent-infringing imports, ITC baseband chip set patent infringement remedy, intellectual property exclusivity and protections in trade agreements\nPiracy of online and streaming copyrighted content\nCompulsory licensing - S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act), S. 102/H.R. 465 (Prescription Drug Price Relief Act), S. 977 (Transparent Drug Pricing Act)\nNIST Return on Investment Initiative for Unleashing American Innovation\nS. 344/H.R. 990 (Hatch-Waxman Integrity Act)\nFTC/patent licensing as exclusive property right\nBayh-Dole Act/technology transfer, march-in rights\nProcedural and evidentiary standards used at Patent Trial and Appeal Board\nPTO patentable subject matter eligibility guidance\nSection 101 patentable subject matter reform\nInjunctive relief from willful infringement\nDOJ-DOC withdrawal of 2013 Policy Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments\nS. 1273/H.R. 2426 (Copyright Alternative in Small-Claims Enforcement (CASE) Act)\nS. 1416 (Affordable Prescriptions for Patients Act)\nObviousness/No Combination Drug Patents Act\nH.R. 4398/H.R. 5133 (Affordable Prescriptions for Patients Through Promoting Competition Act)\nH.R. 3991 (Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act)\nH.R. 5478 (Inventor Rights Act)\nPatent licensing/standards-essential patents/U.S. technological leadership in 5G and other technologies/economic and national security implications\nDOJ-PTO-NIST 2019 revised Joint Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments\nEfficient infringement\nDigital Millennium Copyright Act modernization", "Council on Environmental Quality (CEQ),Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Patent & Trademark Office (PTO),SENATE,U.S. Trade Representative (USTR)", 60000, null, 0, 0, "2020-04-13T14:37:10.683000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2424072"], "units": {}, "query_ms": 0.34580200008349493, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}